• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    11/19/25 4:05:09 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LIMITED

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor

    New York, NY 10177

    929-215-4832

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

      

    Entry into Material Agreements

     

    On November 14, 2025, Paranovus Entertainment Technology Limited (the “Company”) signed a promissory note purchase agreement (the “Purchase Agreement”) with Chicshak Inc., a New York corporation (the “Lender”), which is an unaffiliated entity with respect to the Company. Pursuant to the Purchase Agreement, the Company issued a promissory note with a simple interest rate of 8% per annum and with principal amount of $300,000 (the “Note”) to the Lender on November 14, 2025, the closing date of this transaction (the “Note Offering”). The Note will mature in 12 months after its issuance and can be pre-paid in part or in whole by the Company prior to its maturity date. The net proceeds from the Note Offering will be used to for the general working capital purposes of the Company.

     

    The Purchase Agreement and the Note are attached hereto as Exhibits 10.1 and 10.2. The foregoing descriptions of the Purchase Agreement and the Note are summaries of the material terms of such agreements, and do not purport to be complete and are qualified in their entirety by reference to the Purchase Agreement and the Note.

     

    Exhibits

     

    Exhibit No.

     

    Description

    10.1

     

    The Promissory Note Purchase Agreement, dated November 14, 2025

    10.2

     

    The Promissory Note issued on November 14, 2025

     

     

    2

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Paranovus Entertainment Technology Limited

     

     

     

     

     

    Date: November 19, 2025

    By:

    /s/ Xiaoyue Zhang

     

     

    Name:

    Xiaoyue Zhang

     

     

    Title:

    Chief Executive Officer

     

     

     

    3

     

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Turnarounds and 18,000% Growth

    DENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Markets opened the week with a burst of small-cap energy as several niche innovators, spanning luxury foods, next-gen biomaterials, and RNA therapeutics, delivered updates that injected fresh optimism into the narrative before the opening bell: Top Wealth Group (NASDAQ:TWG) Signals a Turnaround Year Top Wealth Group, the premium caviar and fine-wine supplier, set an upbeat tone after projecting no less than $4 million in net profit for FY2025, marking a powerful reversal from last year's $2 million loss. Management attributed the rebound to operational improvements realized throughout 2024. CEO Kim Kwan Kings, Wong said, "We have worked diligent

    12/8/25 9:43:58 AM ET
    $PAVS
    $TWG
    $WVE
    Medicinal Chemicals and Botanical Products
    Health Care
    Packaged Foods
    Consumer Staples

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/5/25 8:31:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Paranovus Entertainment Technology Ltd.

    EFFECT - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/4/25 12:15:29 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/3/25 7:58:54 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("the Company"), listed on Nasdaq, today announced its financial results for the six months ended September 30, 2025, achieving substantial revenue increase and a meaningful improvement in gross profit following its strategic transformation and acquisition-led growth strategy. The Company reported: Total revenue of $12,413,039 for the six months ended September 30, 2025, compared to $68,454 in the prior-year period, representing ~18,037% year-over-year growth.Net profit attributable to the Compan

    12/5/25 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care